Introduction: Why Nitrosamines Require a Distinct Focus Within ICH M7 Genotoxic Impurity Testing When ICH M7 was finalized in 2014, […]
Genotoxic Impurity Testing: Where Nitrosamines Fit Within the Broader ICH M7 Framework Read More »
Introduction to Nitrosamine Lifecycle Management Nitrosamine Lifecycle Management is essential for maintaining effective control of nitrosamine impurities after pharmaceutical products
Lifecycle Management of Nitrosamine Control Strategies Post-Approval Read More »
Introduction The Nitrosamine Risk in Solid vs Liquid Dosage forms has become a critical topic in pharmaceutical quality and regulatory
Nitrosamine Risk in Solid Oral Dosage vs Liquid Formulations: Comparative Analysis Read More »
Introduction Nitrosamine Testing for OTC Products demands a risk-based and stability-focused approach that goes beyond traditional impurity testing. Over-the-counter medicines
Nitrosamine Testing for Over-the-Counter (OTC) Products: Special Considerations Read More »
Introduction: The Nitrosamine Batch Release Testing Requirement becomes mandatory when confirmatory testing shows nitrosamine impurity levels above 10% of the
Nitrosamine Batch Release Testing: When Is Routine Testing Required? Read More »
Introduction: Why Nitrosamine Testing Highly Potent APIs Requires Specialized Expertise Nitrosamine Testing Highly Potent APIs demands highly sensitive analytical methods,
Nitrosamine Testing in Controlled Substances and Highly Potent APIs (HPAPIs) Read More »
Introduction: Applying a Nitrosamine Reformulation Strategy Without Compromising Bioequivalence A structured Nitrosamine Reformulation Strategy can block nitrosamine formation pathways while
Introduction In this NDMA Root Cause Investigation Case Study, we examine a real-world scenario involving an unexpected spike of N-nitrosodimethylamine
Case Study: Root Cause Investigation of Unexpected NDMA Spike in Finished Product Read More »
Introduction Nitrosamine Testing CRO Selection requires detailed scientific evaluation and regulatory awareness. Global authorities continue to update nitrosamine guidance, and
Selecting the Right Nitrosamine Testing CRO: A Technical Due Diligence Checklist Read More »
Introduction: The global pharmaceutical industry is facing strict regulatory control for mutagenic impurities, especially nitrosamines. A strong understanding of NDA
NDA vs ANDA Nitrosamine Data Requirements: What Sponsors Must Submit Read More »
